Bharat Biotech
Search results
At Biological E. Limited, we nurture healthy living through products that help the treatment and prevention of diseases.
Biological E. Limited continues to evolve as an organisation and currently has three strategic business units: Branded Formulations, Speciality Generic Injectables and Vaccines & Biologics.
Biological E Limited (also known as BioE) is an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana. It specialises in the areas of low-cost vaccine production.
Biological E. Limited | 61,961 followers on LinkedIn. Celebrating Life Everyday | Biological E. Limited (BE), the first private sector biological products company in India and the first...
With a diverse business portfolio that includes pharmaceuticals, vaccines, synthetic biology / fermentation-based APIs and that caters to both the domestic and international markets, Biological E. Limited offers career development opportunities across diverse businesses in the pharmaceuticals / biotech space.
Aug 13, 2020 · What is Biological E, the Indian company producing Corbevax? The Guardian. January 15, 2022. The US through DFC to help Finance Biological E Ltd. COVID-19 Vaccine Manufacturing Efforts. The White House. March 12, 2021. India's Biological E looking to make 600 million J&J vaccine shots a year. Reuters. Feb 10, 2021.
Nov 16, 2020 · Biological E. Limited (BE), a Hyderabad -based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first...
Jul 22, 2022 · Hyderabad: Biological E Ltd (BE) on Thursday announced their expansion plans for investment of more than Rs 1,800 crore and employment creation of more than 2500 people in their three facilities in Genome Valley, Hyderabad. The expansion is primarily targeted to ramp up the manufacturing of vaccines along with generic injectables and R&D.
Dec 7, 2020 · News. Innovation. Hyderabad's Biological E: The dark horse in India's vaccine race. Biological E has forged multiple deals to co-develop and manufacture Covid-19 vaccines, and is prepared...
The ratings upgrade considers the robust revenue growth of Biological E. Limited (BEL/the company) in FY2022 with healthy margins, and the expected uptick in the vaccine and pharmaceutical segments, going forward.
